Objectives : This study was conducted to investigate the effect of Dangguisu-san plus Dangguijakyak-san (DPD) on inflammation and thrombosis.
Methods :
In RAW264.7, after DPD addition, we observed changes in the survival rate of cells, NO production, gene expression of inflammatory cytokine(IL-1β, IL-6, TNF-α), COX-2 and protein expression of the MAP kinase(ERK, JNK, P38). In Human umbilical vein endothelial cell(HUVEC), we observed changes in gene expression and generation of MCP-1, ICAM-1, VCAM-1, KLF2, and eNOS.
DPD was oral administered to rats, which were induced blood stasis by dextran and the number of platelets, the amount of fibrinogen and the time of prothrombin (PT), and the activation part of thromboplastin (APTT) were compared with control group.
Results :
1. RAW264.7 and HUVEC showed a survival rate of less than 90% at 400, 800 DPD(㎍/㎖/DPD) each.
2. In RAW264.7, Amount of NO production and TNF-α gene expression were significantly reduced dose-dependently in all DPD treatments. IL-6 and COX-2 showed significant reductions at above 100 DPD and IL-1β at 200 DPD.
3. In RAW264.7, Amount of protein expression of JNK and P38 was significantly reduced at over 100 DPD, but ERK was not significant.
4. In HUVEC, The gene expression of MCP-1, ICAM-1, and VCAM-1 was significantly reduced at above 200 DPD. The generation of MCP-1, ICAM-1, VCAM-1 showed significant reduction at over 400 DPD, 100 DPD, 200 DPD each.
5. In HUVEC, Amount of KLF2 gene expression and generation were not affected by DPD. Although the gene expression of eNOS was not affected, the production increased significantly at 400 DPD.
6. In vivo, the platelet count was significantly reduced at 400 DPD. And significant reductions in the amount of fibrinogen and significant increases in PT and APTT were seen in all experimental groups.
Conclusion :
Based on the above results, it has been verified experimentally that DPD's anti-inflammatory and anti-thrombotic effects, and it can be expected to be widely used in blood stasis diseases in the future.